A drug composition for delivery to the suprachoroidal space or supraciliary space comprising a flexible solid elongate body for injection into the suprachoroidal space or supraciliary space, wherein the flexible solid elongate body comprises: (i) a plurality of spherical particles comprising a drug, and (ii) at least one excipient that acts as a binder to form the spherical particles into the flexible solid, wherein said spherical particles comprise a biodegradable or bioerodable polymer that undergoes biodegradation or bioerosion in the suprachoroidal space or supraciliary space after injection, wherein said biodegradable or bioerodable polymer is selected from the group consisting of polyhydroxybutyrate, polydioxanone, polyorthoester, polycaprolactone, polycaprolactone copolymers, polycaprolactone-polyethylene glycol copolymers, polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer and/or polylactic-glycolic acid-ethylene oxide copolymer, and wherein the binder comprises either (i) a water soluble polymer or (ii) a lipid or fatty acid, wherein said binder undergoes dissolution in the physiological conditions of the suprachoroidal space or supraciliary space after injection to allow the spherical particles to disperse and migrate into the suprachoroidal space or supraciliary space, wherein the lipid or fatty acid has a melt transition temperature greater than 20 degrees centigrade and up to 37 degrees centigrade. (i) a plurality of spherical particles comprising a drug, and (ii) at least one excipient that acts as a binder to form the spherical particles into the flexible solid, wherein said spherical particles comprise a biodegradable or bioerodable polymer that undergoes biodegradation or bioerosion in the suprachoroidal space or supraciliary space after injection, wherein said biodegradable or bioerodable polymer is selected from the group consisting of polyhydroxybutyrate, polydioxanone, polyorthoester, polycaprolactone, polycaprolactone copolymers, polycaprolactone-polyethylene glycol copolymers, polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer and/or polylactic-glycolic acid-ethylene oxide copolymer, and wherein the binder comprises either (i) a water soluble polymer or (ii) a lipid or fatty acid, wherein said binder undergoes dissolution in the physiological conditions of the suprachoroidal space or supraciliary space after injection to allow the spherical particles to disperse and migrate into the suprachoroidal space or supraciliary space, wherein the lipid or fatty acid has a melt transition temperature greater than 20 degrees centigrade and up to 37 degrees centigrade. wherein said spherical particles comprise a biodegradable or bioerodable polymer that undergoes biodegradation or bioerosion in the suprachoroidal space or supraciliary space after injection, wherein said biodegradable or bioerodable polymer is selected from the group consisting of polyhydroxybutyrate, polydioxanone, polyorthoester, polycaprolactone, polycaprolactone copolymers, polycaprolactone-polyethylene glycol copolymers, polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer and/or polylactic-glycolic acid-ethylene oxide copolymer, and wherein the binder comprises either (i) a water soluble polymer or (ii) a lipid or fatty acid, wherein said binder undergoes dissolution in the physiological conditions of the suprachoroidal space or supraciliary space after injection to allow the spherical particles to disperse and migrate into the suprachoroidal space or supraciliary space, wherein the lipid or fatty acid has a melt transition temperature greater than 20 degrees centigrade and up to 37 degrees centigrade.